Evidence map›Paper›PMID 35743805›Full record

ArticleLife (Basel, Switzerland)2022

Using Machine Learning to Detect Theranostic Biomarkers Predicting Respiratory Treatment Response.

Vasilis Nikolaou, Sebastiano Massaro, Masoud Fakhimi, Wolfgang Garn

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Vasilis NikolaouBusiness School, University of Surrey, Guildford GU2 7XH, UK.ORCID 0000-0002-2768-5340
Sebastiano MassaroBusiness School, University of Surrey, Guildford GU2 7XH, UK.ORCID 0000-0001-8581-8546
Masoud FakhimiBusiness School, University of Surrey, Guildford GU2 7XH, UK.ORCID 0000-0002-7144-7868
Wolfgang GarnBusiness School, University of Surrey, Guildford GU2 7XH, UK.ORCID 0000-0003-2278-8997
University of Surrey · GB

Funding

University of Surrey GB 688953065
6 · The paper itself

Abstract

backgroundTheranostic approaches-the use of diagnostics for developing targeted therapies-are gaining popularity in the field of precision medicine. They are predominately used in cancer research, whereas there is little evidence of their use in respiratory medicine. This study aims to detect theranostic biomarkers associated with respiratory-treatment responses. This will advance theory and practice on the use of biomarkers in the diagnosis of respiratory diseases and contribute to developing targeted treatments.

methodsWe performed a cross-sectional analysis on a sample of 13,102 adults from the UK household longitudinal study 'Understanding Society'. We used recursive feature selection to identify 16 biomarkers associated with respiratory treatment responses. We then implemented several machine learning algorithms using the identified biomarkers as well as age, sex, body mass index, and lung function to predict treatment response.

resultsOur analysis shows that subjects with increased levels of alkaline phosphatase, glycated haemoglobin, high-density lipoprotein cholesterol, c-reactive protein, triglycerides, hemoglobin, and Clauss fibrinogen are more likely to receive respiratory treatments, adjusting for age, sex, body mass index, and lung function.

conclusionsThese findings offer a valuable blueprint on why and how the use of biomarkers as diagnostic tools can prove beneficial in guiding treatment management in respiratory diseases.

Indexed as

biomarkersdiagnosismachine learningtreatment response

Identifiers

PMID35743805
PMCPMC9224718
OpenAlexW4281477654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.